数字孪生在炎症性肠病中的应用:连接数据、生物学与试验创新
炎症性肠病临床试验面临复杂性增加、成本高和招募困难。数字孪生是数据驱动的个体患者虚拟副本,可模拟疾病轨迹和治疗反应,有望生成合成对照组、实现适应性随机化并预测复发或治疗反应。本文综述其转化潜力及验证、数据治理、算法偏倚和监管伦理挑战。
要点
- 数字孪生可生成合成对照组并实现适应性随机化,提升统计效能。
- 早期肿瘤、心脏和内分泌研究显示数字孪生可行且可减轻患者负担。
- 整合至IBD试验需严格验证框架、透明数据治理及关注算法偏倚。
核心结论
- 数字孪生有望通过计算机模拟和适应性设计变革IBD临床试验,但需解决验证、治理和伦理挑战。
研究设计与样本
- 综述文章,探讨数字孪生在IBD临床试验中的应用潜力与挑战。
主要发现
- 数字孪生基于临床、分子、影像和真实世界多模态数据构建,可模拟疾病轨迹和治疗反应。
- 数字孪生可生成合成对照组、实现适应性随机化并预测疾病复发或治疗反应。
- 肿瘤、心脏和内分泌早期研究显示数字孪生可行,可提升统计效能并减轻患者负担。
临床怎么用
- 数字孪生可用于IBD临床试验设计,如合成对照组和适应性随机化,以提升效率。
- 应用时需建立严格验证框架、透明数据治理并关注算法偏倚和知情同意。
局限性
- 整合数字孪生至IBD临床试验需应对监管、伦理和后勤挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clinical trials in IBD face difficulties of escalating complexity, high costs and challenges in recruitment. Digital twins are virtual, data-driven replicas of individual patients that model disease trajectories and treatment responses, which offer a potential innovative change in the conduct of clinical trials in IBD. Built from multimodal datasets integrating clinical, molecular, imaging and real-world data, digital twins can generate synthetic control arms, enable adaptive randomisation and predict disease relapse or treatment response. Early studies across oncology, cardiology and endocrinology demonstrate their feasibility and potential to improve statistical power while reducing patient burden. However, the integration of digital twins into clinical trials in IBD will require rigorous validation frameworks, transparent data governance and attention to algorithmic bias and consent. In this review, we explore how digital twins may transform IBD research-from in silico simulation to adaptive, patient-centred trial design-and outline the regulatory, ethical and logistical challenges to be considered in order to successfully integrate them into future trials.
引用
- Colwill M, Honap S, Young AM, et al. Digital twins in IBD-bridging data, biology and trial innovation. Gut. 2026. PMID: 42055788. doi:10.1136/gutjnl-2026-338447
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。